NCT03226431View on ClinicalTrials.gov

Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0

PHASE1CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

December 11, 2017

Primary Completion Date

June 25, 2019

Study Completion Date

June 25, 2019

Conditions

Lung Transplant

Interventions

DRUG

Ascorbic Acid

ARINA-1 (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

lead

Duke University

OTHER

NCT03226431 - Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0 | Biotech Hunter | Biotech Hunter